CONTEXT THERAPEUTICS INC (CNTX) Fundamental Analysis & Valuation

NASDAQ:CNTX • US21077P1084

Current stock price

2.71 USD
+0.07 (+2.65%)
Last:

This CNTX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. CNTX Profitability Analysis

1.1 Basic Checks

  • In the past year CNTX has reported negative net income.
  • In the past year CNTX has reported a negative cash flow from operations.
  • In the past 5 years CNTX always reported negative net income.
  • CNTX had a negative operating cash flow in each of the past 5 years.
CNTX Yearly Net Income VS EBIT VS OCF VS FCFCNTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2019 2020 2021 2022 2023 2024 2025 0 -10M -20M -30M

1.2 Ratios

  • The Return On Assets of CNTX (-52.74%) is worse than 65.10% of its industry peers.
  • CNTX has a Return On Equity of -59.73%. This is comparable to the rest of the industry: CNTX outperforms 47.40% of its industry peers.
Industry RankSector Rank
ROA -52.74%
ROE -59.73%
ROIC N/A
ROA(3y)-76.39%
ROA(5y)-57.73%
ROE(3y)-96.55%
ROE(5y)-70.8%
ROIC(3y)N/A
ROIC(5y)N/A
CNTX Yearly ROA, ROE, ROICCNTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2019 2020 2021 2022 2023 2024 2025 0 1K -1K -2K

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for CNTX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CNTX Yearly Profit, Operating, Gross MarginsCNTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2019 2020 2021 2022 2023 2024 2025

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. CNTX Health Analysis

2.1 Basic Checks

  • Compared to 1 year ago, CNTX has more shares outstanding
  • The number of shares outstanding for CNTX has been increased compared to 5 years ago.
  • CNTX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
CNTX Yearly Shares OutstandingCNTX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M
CNTX Yearly Total Debt VS Total AssetsCNTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M

2.2 Solvency

  • CNTX has an Altman-Z score of 14.62. This indicates that CNTX is financially healthy and has little risk of bankruptcy at the moment.
  • CNTX has a Altman-Z score of 14.62. This is amongst the best in the industry. CNTX outperforms 87.50% of its industry peers.
  • CNTX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 14.62
ROIC/WACCN/A
WACCN/A
CNTX Yearly LT Debt VS Equity VS FCFCNTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2019 2020 2021 2022 2023 2024 2025 0 20M -20M 40M 60M 80M

2.3 Liquidity

  • A Current Ratio of 8.52 indicates that CNTX has no problem at all paying its short term obligations.
  • CNTX's Current ratio of 8.52 is fine compared to the rest of the industry. CNTX outperforms 78.65% of its industry peers.
  • A Quick Ratio of 8.52 indicates that CNTX has no problem at all paying its short term obligations.
  • With a decent Quick ratio value of 8.52, CNTX is doing good in the industry, outperforming 78.65% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 8.52
Quick Ratio 8.52
CNTX Yearly Current Assets VS Current LiabilitesCNTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. CNTX Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 28.30% over the past year.
EPS 1Y (TTM)28.3%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-250%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • CNTX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 23.10% yearly.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-13.94%
EPS Next 2Y-3.62%
EPS Next 3Y1.11%
EPS Next 5Y23.1%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CNTX Yearly Revenue VS EstimatesCNTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2028 2029 2030 2031 2032 2033 200M 400M 600M
CNTX Yearly EPS VS EstimatesCNTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 2 -2 -4 -6 -8

More info and screens

Find the best growth stocksShow best growing peers

0

4. CNTX Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for CNTX. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CNTX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CNTX Price Earnings VS Forward Price EarningsCNTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CNTX Per share dataCNTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 -0.4 0.6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-3.62%
EPS Next 3Y1.11%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. CNTX Dividend Analysis

5.1 Amount

  • No dividends for CNTX!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

CNTX Fundamentals: All Metrics, Ratios and Statistics

CONTEXT THERAPEUTICS INC

NASDAQ:CNTX (4/9/2026, 10:54:05 AM)

2.71

+0.07 (+2.65%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)03-23
Earnings (Next)05-01
Inst Owners76.61%
Inst Owner Change0%
Ins Owners1.25%
Ins Owner Change0%
Market Cap248.99M
Revenue(TTM)N/A
Net Income(TTM)-36.12M
Analysts83.75
Price Target5.78 (113.28%)
Short Float %1.42%
Short Ratio0.88
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-16.69%
Min EPS beat(2)-29.36%
Max EPS beat(2)-4.02%
EPS beat(4)1
Avg EPS beat(4)-15.59%
Min EPS beat(4)-44.18%
Max EPS beat(4)15.19%
EPS beat(8)4
Avg EPS beat(8)-1.7%
EPS beat(12)4
Avg EPS beat(12)-17.22%
EPS beat(16)8
Avg EPS beat(16)-10.11%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)13.33%
PT rev (3m)6.25%
EPS NQ rev (1m)-0.63%
EPS NQ rev (3m)-2.46%
EPS NY rev (1m)0%
EPS NY rev (3m)-2.44%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 4.12
P/tB 4.12
EV/EBITDA N/A
EPS(TTM)-0.38
EYN/A
EPS(NY)-0.43
Fwd EYN/A
FCF(TTM)-0.29
FCFYN/A
OCF(TTM)-0.29
OCFYN/A
SpS0
BVpS0.66
TBVpS0.66
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -52.74%
ROE -59.73%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-76.39%
ROA(5y)-57.73%
ROE(3y)-96.55%
ROE(5y)-70.8%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 208.59%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 8.52
Quick Ratio 8.52
Altman-Z 14.62
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)91.85%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)28.3%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-250%
EPS Next Y-13.94%
EPS Next 2Y-3.62%
EPS Next 3Y1.11%
EPS Next 5Y23.1%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-31.37%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-81.4%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-81.26%
OCF growth 3YN/A
OCF growth 5YN/A

CONTEXT THERAPEUTICS INC / CNTX Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for CONTEXT THERAPEUTICS INC?

ChartMill assigns a fundamental rating of 3 / 10 to CNTX.


What is the valuation status of CONTEXT THERAPEUTICS INC (CNTX) stock?

ChartMill assigns a valuation rating of 0 / 10 to CONTEXT THERAPEUTICS INC (CNTX). This can be considered as Overvalued.


Can you provide the profitability details for CONTEXT THERAPEUTICS INC?

CONTEXT THERAPEUTICS INC (CNTX) has a profitability rating of 0 / 10.


What is the financial health of CONTEXT THERAPEUTICS INC (CNTX) stock?

The financial health rating of CONTEXT THERAPEUTICS INC (CNTX) is 8 / 10.